We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $0.48 | — | — | $417.62M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.33 | — | — | $382.65M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.34 | — | — | $1.17B |
Consensus PT $17.43 · 7 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Citigroup | — | 투자의견 상향 | Sell → Neutral | — | Citigroup: Sell → Neutral |
| 2026. 05. 07. | Citigroup | — | 의견 유지 | Sell → Sell | — | Citigroup: Sell |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.2 | — | — | $787.05M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Stored first · Google News · Yahoo Finance (English)
Integra LifeSciences Holdings (IART) Is Up 6.2% After Earnings Beat And Outlook Raise Has The Bull Case Changed? - simplywall.st
Integra LifeSciences Holdings (IART) Is Up 6.2% After Earnings Beat And Outlook Raise Has The Bull Case Changed? simplywall.st
Integra LifeSciences Appoints Essig CEO, Adds Commercial Chief - thekeyexecutives.com
Integra LifeSciences Appoints Essig CEO, Adds Commercial Chief thekeyexecutives.com
Integra LifeSciences names Stuart Essig as CEO - MSN
Integra LifeSciences names Stuart Essig as CEO MSN
Integra LifeSciences Hits Day High with 8.36% Surge in Stock Price - Markets Mojo
Integra LifeSciences Hits Day High with 8.36% Surge in Stock Price Markets Mojo
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue? Yahoo Finance
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue?